Skip to main content
Premium Trial:

Request an Annual Quote

DxTerity Buys Cancer Dx Rights from SourceMDx

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Genetic testing technology company DxTerity Diagnostics said today that it has acquired the intellectual property rights to several blood-based cancer diagnostic tests from SourceMDx.

The IP covers gene expression assays for early diagnosis of breast and lung cancer and a test for determining survival and response to therapy for melanoma patients. They are covered by a portfolio of more than 30 US and international patent filings.

The Los Angeles-based firms said that it has begun migrating these tests to function on its Non-Enzymatic Amplification Technology (NEAT) platform, which is designed to make genetic testing easier and cheaper.

The NEAT technology eliminates the need for sample purification and enzymatic amplification, and it is based on technology DxTerity has licensed from Stanford University, where it was developed.

"The NEAT platform is perfect for blood-based genomic testing since it enables the simultaneous direct-from-sample measurement of up to 40 gene targets," DxTerity CEO Bob Terbrueggen said in a statement.

Financial terms of the agreement were not disclosed.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.